Functional impact of high clopidogrel maintenance dosing in patients undergoing elective percutaneous coronary...

Area of Science:

• Cardiology
• Pharmacology
• Thrombosis

Background:

• The standard maintenance dose of clopidogrel (75 mg/day) may not provide adequate platelet inhibition in all patients undergoing elective percutaneous coronary intervention (PCI).
• Higher doses of clopidogrel might offer improved antiplatelet effects, but require further investigation in the context of PCI.

Purpose of the Study:

• To evaluate the functional impact of a high maintenance dose (150 mg/day) of clopidogrel on platelet aggregation in patients undergoing elective PCI.
• To compare the antiplatelet effects of 150 mg/day versus 75 mg/day clopidogrel maintenance doses.

Main Methods:

• A prospective, randomized, platelet function study involving elective PCI patients.
• Patients were assigned to either a 75 mg (n=20) or 150 mg (n=20) daily maintenance dose of clopidogrel for 30 days.
• Platelet aggregation was measured using light transmittance aggregometry with adenosine diphosphate (ADP) stimuli at 30 days and after resuming standard dosing.

Main Results:

• Patients receiving 150 mg/day clopidogrel exhibited significantly lower ADP-induced platelet aggregation compared to those on 75 mg/day (52.1% vs. 64.0% at 20 microM ADP, p < 0.001).
• A dose-dependent effect was confirmed by increased platelet aggregation upon resuming standard dosing (p < 0.001).
• Similar findings were observed with 5 microM ADP stimuli, and significant variability in antiplatelet effects was noted across patients.

Conclusions:

• A 150 mg/day maintenance dose of clopidogrel demonstrates superior platelet inhibition compared to the standard 75 mg/day dose in patients undergoing elective PCI.
• This higher dose regimen may offer enhanced antiplatelet effects, potentially improving outcomes in this patient population.
• Further research is warranted to confirm these findings and assess clinical implications.